Physician profile
Libby Long
NPI 1083608764
$3,223.18
in general payments reported to CMS, 2019-2025
28 companies · $752 in 2025
The $752 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $287 · 2021: $400 · 2022: $374 · 2023: $521 · 2024: $609 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,881.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $947.32 | 2022-2025 | Azstarys |
| Tris Pharma INC | $464.00 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $308.14 | 2019-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $236.63 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $234.24 | 2019-2025 | Elaprase, Gattex |
| Adlon Therapeutics L.P. | $156.57 | 2020-2021 | |
| Glaxosmithkline, LLC. | $135.60 | 2019-2025 | Bexsero, Pediarix |
| Merck Sharp & Dohme LLC | $103.79 | 2019-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $77.47 | 2024-2025 | |
| Cranial Technologies, INC | $61.41 | 2020-2025 | Doc Band |
| Shire North American Group INC | $59.83 | 2019 | |
| Sobi, INC | $45.45 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $40.36 | 2021-2023 | Qelbree |
| Neos Therapeutics, Lp | $37.41 | 2022-2023 | Cotempla Xr-Odt |
| Ars Pharmaceuticals Operations, INC. | $34.33 | 2025 | Neffy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $30.30 | 2020 | |
| Alexion Pharmaceuticals, INC. | $27.80 | 2020-2023 | Strensiq |
| Kaleo, INC. | $27.30 | 2020 | |
| Azurity Pharmaceuticals, INC. | $25.45 | 2024 | Triptodur |
| Avion Pharmaceuticals | $23.77 | 2023 | Methylphenidate Hydrochloride |
| Sanofi Pasteur INC. | $23.64 | 2023 | |
| Novartis Pharmaceuticals Corporation | $22.81 | 2019 | |
| Seqirus USA INC | $19.02 | 2021 | |
| Pfizer INC. | $18.66 | 2020 | |
| Vertical Pharmaceuticals, LLC | $17.32 | 2024 | Relexxii |
| Cipher Pharmaceuticals US LLC | $15.81 | 2025 | Natroba, Spinosad |
| Phadia US INC. | $14.58 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $14.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Libby Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.